BURNABY, BRITISH COLUMBIA--(Marketwire - Oct 12, 2012) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD) ("LED" or the "Company") announces that, subject to TSX Venture Exchange approval, it has agreed to extend the term of certain warrants to acquire a total of 5,599,897 common shares of the Company that are scheduled to expire between October 31, 2012 and February 22, 2013. The extension ranges from between three to seven months. As a result of the extension, all outstanding series of LED warrants will now expire on May 22, 2013, other than warrants previously granted to one of LED''s product distributors. The warrants were originally issued between July 9, 2010 and February 22, 2011 when the Company was a private issuer, and have exercise prices ranging from $0.65 to $1.00 per common share.
About LED Medical Diagnostics Inc.
LED Medical Diagnostics Inc. was founded in 2003 and is headquartered in Burnaby, British Columbia, Canada. Its wholly-owned subsidiary, LED Dental Inc., is the manufacturer of the VELscope Vx Enhanced Oral Assessment System. VELscope Vx devices, the first to apply tissue fluorescence visualization technology to the oral cavity, are used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device in the world. To date, the VELscope has sold over 12,000 units, and been used to perform an estimated 20 million exams. For more information, call +1 (604) 434-4614, or visit www.velscope.com.
About the VELscope Vx
The Velscope Vx is a powerful FDA-approved tool used to screen for oral cancer. It saves lives and decreases mortality by helping clinicians detect early stage oral cancer, pre-cancer, and other abnormalities in the mouth such as viral, fungal and bacterial infections. For more information please call +1 (604) 434-4614, or visit www.velscope.com.